Invalidity dossier
US 9249213
Human cytomegalovirus neutralizing antibodies and use thereof
Current assignee: Institute for Research in Biomedicine
Added 9/21/2026, 10:46:08 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US9249213B2
Title: Human cytomegalovirus neutralizing antibodies and use thereof
Patent number: US9249213B2 | Application number: US14/815,162 | Publication: US20150353627A1
Inventors: Antonio Lanzavecchia and Annalisa Macagno
Assignee: Institute for Research in Biomedicine (IRB); originally assigned to Institute for Research in Biomedicine IRB (assignment recorded 2015-09-03)
Key dates: Priority date 2008-07-16; filing date 2015-07-31; granted/publication date 2016-02-02; anticipated expiration 2029-07-15. Legal status listed as "Expired - Fee Related."
Purpose and plain-language scope: The patent concerns human antibodies that neutralize human cytomegalovirus (HCMV) and uses of those antibodies. The prior-art keywords listed are "antibody," "HCMV," "SEQ," "antibodies," and "UL131A," indicating the antibodies relate to HCMV and to the UL131A protein. Classifications place it in antibody/Virology areas — C07K16/089 (Cytomegalovirus), C07K16/081 (DNA viruses), A61K39/42 (viral antibodies), and A61P31/22 (antivirals for herpes viruses). The classification data also references antibody features such as human origin (C07K2317/21), complementarity determining regions/CDRs (C07K2317/565), Fab/F(ab')2 and single-chain antibody (scFv) fragments, glycosylation, and epitope identification.
In plain terms, the excerpt indicates this patent covers human-derived HCMV-neutralizing antibodies, including antibody fragments and CDR-based features, and therapeutic/antiviral uses. The record also notes a first worldwide family litigation filing (Darts-ip link) and later applications claiming priority from this family (e.g., US15/284,799, US16/025,296, US16/527,836).
What the excerpt does not establish: The supplied text does not include the actual claims, detailed description, sequence listings, examples, or figures. It therefore does not establish the precise claimed antibody sequences, epitopes, dosing, formulation, or specific therapeutic indications, nor any validity, infringement, or ownership conclusions beyond the recorded assignment.
Source: https://patents.google.com/patent/[US9249213](/patent/US9249213)/en
Generated 10/1/2026, 10:01:10 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 9249213. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.